A trimodal treatment approach for elderly patients with locally advanced rectal cancer remains a hotly debated topic. We investigated an intensified neoadjuvant chemoradiotherapy regimen. The results were encouraging, with good treatment tolerance, low severe toxicity rates, and valid 5-year survival outcomes. Intensified neoadjuvant treatment could be proposed for elderly patients with locally advanced rectal cancer. Introduction: We report the treatment compliance, toxicity rates, and long-term clinical outcomes of elderly patients who received intensified neoadjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC). The 5-year overall survival and disease-free survival rates were 70.6% and 65.5%, respectively. Conclusions: Intensified neoadjuvant CRT is an efficacious and safe treatment option for LARC in elderly patients.
Introduction
It has been well demonstrated that elderly patients are grossly underrepresented in clinical trials, constituting < 10% of patients enrolled. 1 Although during the past decade, the rectal tumor incidence has declined in those aged 70 years, definitive clinical data to guide treatment decisions among those patients aged 70 years are scarce. 2 Generally, the reference standard therapy for locally advanced rectal cancer (LARC) is a trimodality approach, including neoadjuvant 5-fluoropyrimidineebased chemoradiotherapy (CRT), followed by surgery and adjuvant chemotherapy. 3 However, it bears a distant metastasis rate of > 30%. A recent meta-analysis suggested a significant clinical benefit in terms of distant failure by adding oxaliplatin to the standard fluoropyrimidine-based CRT. 4 However, among the trials included, it was not possible to extrapolate patient age details; thus, a subsequent subset analysis was not performed. Definitive conclusions are still pending, and further clinical data are paramount to better clarify the precise role of the intensified neoadjuvant approach, especially for elderly patients.
We have realized the importance of analyzing the efficacy and toxicity of multimodal therapy in patients aged 70 years. The present study was planned to understand the treatment effects among elderly LARC patients.
Patients and Methods

Patient Population
The cases originated from a previously described cohort of LARC patients. 5 We retrospectively reviewed the medical data from all 1 consecutive elderly patients treated for LARC from 2007 to 2014 at our institute. The institutional review board and the scientific review committee approved the study (protocol no. 464/16). All patients provided written informed consent before treatment. Only patients aged 70 years were included in the present analysis. All patients had histologically proven rectal adenocarcinoma, clinically staged using endorectal ultrasonography and total body contrast-enhanced computed tomography (CT) and/or pelvic magnetic resonance imaging (MRI) as T3-T4 with or without positive regional lymph nodes and no evidence of distant metastases. To classify the patients' comorbidities, we used the adult comorbidity evaluation-27 (ACE-27) score, a 27-item validated comorbidity index. 6 
Treatment Protocol
All patients underwent intensified neoadjuvant treatment. Details were described in our previous study. 7 In brief, radiotherapy (RT)
was delivered with a 3-dimensional conformal multiple field technique at a total dose of 45 Gy (1.8 Gy/fraction) to the whole pelvis, plus 5.4 to 9 Gy (1. Five weeks after the end of CRT, the locoregional clinical response was assessed by abdominopelvic CT and/or MRI, using the Response Evaluation Criteria In Solid Tumors guideline. 8 Surgery was planned 7 to 9 weeks after the end of CRT, and the type of surgery was left to the surgeon's discretion. The type of adjuvant chemotherapy was chosen by the oncologist.
Patient Evaluation and Follow-up
Toxicity was scored using the Common Terminology Criteria for Adverse Events, version 4.0. 9 After treatment, all patients were monitored by physical examination and transrectal ultrasonography every 3 months for 2 years and then every 6 months thereafter. Colonoscopy was performed 1 year after surgery and then annually.
To monitor the presence of potentially local recurrence and distant metastasis, both total body CT and pelvic MRI were recommended annually for 5 years after CRT.
Statistical Analysis
Statistical analysis was performed using R-Studio, version 0.98.1091, software. Standard descriptive statistics were used to evaluate the distribution of each variable. Continuous variables are presented as the median and range, and dichotomous variables are presented as percentages.
Overall survival (OS) and disease-free survival (DFS) were calculated in months from the date of the end of CRT to the first event, including the date of the last follow-up examination or death (OS) and/or relapse (DFS). A pathologic complete response (pCR) was defined as the absence of any residual tumor cells detected in the operative specimen, including the primary tumor area, the whole mesorectal fat, and the resected lymph nodes. Patient followup data were updated to a minimum of 2 years. OS and DFS were estimated using the Kaplan-Meier method, and survival curves were compared using the log-rank test.
According to their ACE-27 score (0 or 1), patients were divided into 2 groups. Treatment compliance, the incidence of toxicity, and survival outcomes were compared using the Fisher exact test (F-test) between an ACE-27 score of 0 versus an ACE-27 score of 1. All reported P values are 2 sided, and P values < .05 were considered statistically significant.
Results
Patient Characteristics
A total of 26 patients were included in the present study. The patient and tumor characteristics are listed in Table 1 . The median age at diagnosis was 74 years (range, 70-76 years), and 17 patients had an ACE-27 score of 1. The vast majority of patients (n ¼ 24; 92.3%) had regional lymph node involvement at diagnosis.
Treatment Compliance
All patients completed the scheduled CRT. All patients received the prescribed total RT dose. RT was interrupted for acute toxicity in 5 patients (19.2%). Of these, only 1 patient stopped chemotherapy definitely after 3 cycles. Globally, 85% of patients (n ¼ 22) achieved chemotherapy protocol compliance and received 5 (n ¼ 16; 61.5%) or 6 cycles (n ¼ 6; 23%) of oxaliplatin. After the end of CRT, a clinical complete response was noted in 6 patients (23%). Clinical tumor re-evaluation was stable in only 2 patients (7.7%). Of the 26 patients, 24 (92.3%) underwent surgery. Of the remaining 2 patients, 1 died before surgery and 1 with a clinical Intensified Neoadjuvant CRT for Elderly LARC complete response after CRT was treated to a wait and see approach because of comorbidities (ACE-27 score, 1). Conservative surgery was performed in 16 patients (low anterior resection in 10, transanal endoscopic microsurgery in 2, and a different surgical approach in 4). Miles surgery was performed in 7 patients; thus, a permanent stoma was placed in only 29.2% of patients. One patient died during surgery. None had positive radial margins. A pCR was achieved in 5 patients (19.2%).
Toxicity
All patients had acute toxicity associated with CRT. The incidence details are listed in Table 2 . Gastrointestinal toxicity was the most common acute complication, and proctitis was the most frequent symptom (n ¼ 18; 69.2%). Overall, severe acute toxicity was recorded in 19.2% of cases (n ¼ 5). No hematologic acute toxicity was observed. Late CRT treatment-related toxicity was assessed and involved the following conditions: dermatitis (n ¼ 1), proctitis (n ¼ 6), fecal incontinence (n ¼ 2), and venous thrombotic events (n ¼ 3). A late surgical treatment complication was recorded in 1 patient, which clinically consisted of an anastomotic fistula.
Survival Outcomes
The follow-up data were updated in May 2017. At the date of analysis, 7 patients (26.9%) had died, 16 patients (61.6%) were alive, and 3 patients (11.5%) had been lost to follow-up. The 2-and 5-year OS rates were 86.9% (95% CI, 0.643-0.956) and 70.6% (95% CI, 0.454-0.858), respectively. The 2-and 5-year DFS was estimated at 70.6% (95% CI, 0.466%-0.849%) and 65.5% (95% CI, 0.423%-0.813%), respectively. The details are presented in Figure 1 . Local recurrence was recorded in 2 patients (7.7%). Five patients (19.2%) presented with distant metastasis (liver in 2, lung in 2, and multiple sites in 1).
ACE-27 Score Analysis
At baseline, 9 patients had an ACE-27 score of 0, 14 patients had an ACE-27 score of 1, and 3 patients had an ACE-27 score of 2. Globally, the ACE-27 score had no influence on treatment tolerability (P ¼ .81) or on severe acute toxicity onset (P ¼ .46).
The patients were assigned to 2 groups according to the ACE-27 score (score of 0 or 1). The 5-year OS rate was 83.3% (95% CI, 0.27%-0.98%) for patients with an ACE-27 score of 0 and 64.7% (95% CI, 0.34%-0.84%) with an ACE-27 score of 1 (P ¼ .74). The 5-year DFS was 83.3% (95% CI, 0.27%-0.98%) and 66.8% (95% CI, 0.37%-0.85%) for an ACE-27 of 0 and ACE-27 of 1, respectively (P ¼ .70).
Discussion
The present study has demonstrated that intensified neoadjuvant CRT is efficacious and associated with a low severe toxicity profile. We demonstrated an important pCR rate (19.2%), a considerable absence of permanent stoma (70.8%), and remarkable 5-year OS and DFS rates (70.6% and 65.5%, respectively). All patients had received the total prescribed RT dose, and 5 cycles of oxaliplatin were administered to the vast majority of patients (85%). Increased comorbid conditions (ACE-27 score of 1) were not associated with poor treatment compliance or with a negative effect on survival.
Currently, clinical data comparing an intensified regimen versus standard CRT in the geriatric population have not yet been reported. Trials specifically designed to assess the effect of oxaliplatin-based CRT in elderly LARC patients would be very welcome. At present, we can only provide an indirect comparison of treatments to resolve this issue. The benefit of neoadjuvant CRT was evaluated in several retrospective studies with disappointing results. Data from French and Italian series showed that neoadjuvant CRT in elderly LARC was a well-tolerated treatment, without any significant increase in acute and late toxicities. [10] [11] [12] In contrast, Margalit et al 13 and Cai et al 14 demonstrated a treatment deviation from the programmed therapy course in the vast majority of patients, suggesting that CRT should be performed with caution in elderly patients. Guimas et al 15 had similar observations from their study that included 56 elderly patients. Although, globally, grade 3 acute toxicity was recorded in 14.3% of cases, they noted an increase in morbidity with the addition of oxaliplatin to standard CRT. Globally, the real effect on clinical outcomes is difficult to quantify owing to study heterogeneity, especially in terms of chemotherapy regimens, RT dosage, and follow-up periods. No clear evidence has shown a prolongation of OS and DFS or an increase in the pCR rate. However, in our study, the rate of pCR was 19.2%, comparable to the 17% found in the CAO/ARO/AIO-04 German trial-the only randomized trial that demonstrated a survival benefit with the addition of oxaliplatin in LARC. 16 The ACCORD12/PRODIGE2 Intergroup collected age-related information from their phase III study, in which they compared neoadjuvant fluoropyrimidine-based CRT with dose-intensified RT plus capecitabine and oxaliplatin. 17 To explore the response and tolerance profile in elderly patients, they performed a subgroup analysis and divided entire patient populations into 2 groups by age: < 70 years (n ¼ 442) and 70 years (n ¼ 142). Globally, treatment efficacy (pCR 16.9% vs. 14.7%), postoperative complications (27.6% vs. 27.6%), and 3-year OS (90.7% vs. 80.5%) were similar between the 2 age categories, although tolerance was lower in the elderly patients. A greater incidence of nonhematologic grade 3 toxicity was observed in patients aged 70 years compared with younger patients (13.6% vs. 21.1%; P ¼ .03). In our study, we observed the same acute toxicity trend (19.2%) but a lower incidence of surgical complications and superior treatment efficacy and survival rates. Obviously, the lack of a direct comparison underpowered our analysis. Despite the little evidence to support the use of concomitant oxaliplatin in LARC patients, the question is how to consider elderly patients in daily clinical practice, with only limited evidence-based medicine to support decision making. We have promoted the enrollment of elderly patients into our intensified neoadjuvant setting experience, mainly to offer a possible basis for potentially practice-changing conclusions. Recently, the International Society of Geriatric Oncology declared the urgent need for guidelines to support radiation oncologists, surgeons, and medical oncologists in the treatment of older patients. 18 Although debatable, because not adequately powered, our results could provide a rationale for the use of intensified neoadjuvant CRT for the elderly patient population with LARC, even in the absence of a clear survival benefit. Preexisting comorbidities did not result in costly treatment-related hospitalizations. Additionally, no significant increase occurred in acute and late complications. The choice of chemotherapy regimen intensification was associated with a high pCR rate and survival. Thus, the addition of oxaliplatin to the standard 5-fluoruoracilebased CRT seems to provide clinical benefits, regardless of age and comorbidities. Oxaliplatin seems appropriate and its applicability in elderly patients is not limited. These patients should be treated in specialized centers where the expertise can guarantee the most favorable treatment care.
The present study had a number of potential limitations. It was a retrospective analysis with a modest number of patients, limiting its statistical power. However, to the best of our knowledge, this is the first long-term follow-up analysis showing oncologic outcomes for elderly LARC patients treated with intensified neoadjuvant CRT. Only a few patients were lost to follow-up; therefore, the results were not negatively affected. These results are primarily hypothesisgenerating. Thus, a tailored multicenter trial should be designed to ensure the adequacy of analysis according to age. Intensified neoadjuvant CRT can be considered a valid treatment option for geriatric oncologic management. Although the trimodality strategy remains the standard of care, a more conservative approach such as local excision and a wait-and-see policy should be proposed for those elderly patients with a favorable response (better if a complete clinical or radiologic response) to preoperative CRT. However, more accurate investigations are needed.
Conclusions
Intensified neoadjuvant CRT is a safe treatment approach for elderly LARC patients. It provides an appropriate balance between toxicity risk and clinical outcome benefits. Its precise role in the management of LARC in elderly patients remains to be defined.
Clinical Practice Points
Rectal cancer is a common malignancy, with an increase in cases occurring in elderly patients. In randomized clinical trials, patients aged > 70 years are usually underrepresented. The optimal treatment approach for elderly patients with LARC is currently a matter of debate. On the basis of the improved life expectancy, the neoadjuvant CRT regimen, which includes oxaliplatin and 5-fluorouracil, has been tested. Intensified neoadjuvant CRT seems promising for elderly LARC patients.
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